TLR9 and melanoma: Additionally, in an independent cohort of patients with high-risk resectable melanoma treated with anti–PD-1 and a TLR9 agonist, high sucralose intake was associated with a significantly lower probability of MPR (Fig. 1F) and lower RFS (median 25.0 vs. 19.0 months, log-rank P = 0.012; Fig. 1G; Supplementary Tables S3 and S4C).